by John Conrad | Jul 17, 2024 | NewsBrief
Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, announced that its multimodal immune profile score (IPS) algorithmic test is now available for research use only (RUO). IPS is the first offering of a larger immunotherapy-based...
